Exploring how molecular cloning and expression technologies are creating viral shields against HCMV infection through receptor peptides that block viral fusion.
Discover how researchers are targeting the fusion machinery of human cytomegalovirus (HCMV) to develop new treatments and vaccines by focusing on glycoprotein B's antigenic domain 5.